Market Tracker

12/09 5:16pm ET

Supernus Pharmaceuticals Inc (NASDAQ:SUPN)

23.00
Delayed Data
As of Dec 09
 +0.70 / +3.14%
Today’s Change
9.51
Today|||52-Week Range
26.84
+71.13%
Year-to-Date
What's in the Cards for Nutanix (NTNX) in Q1 Earnings?
Nov 28 / Zacks.com - Paid Partner Content
What's in the Cards for Box, Inc. (BOX) in Q3 Earnings?
Nov 28 / Zacks.com - Paid Partner Content
Top Ranked Income Stocks to Buy for November 28th
Nov 28 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close22.30
Today’s open22.50
Day’s range22.45 - 23.20
Volume649,843
Average volume (3 months)628,964
Market cap$1.1B
Dividend yield--
Data as of 4:00pm ET, 12/09/2016

Growth & Valuation

Earnings growth (last year)-12.50%
Earnings growth (this year)+190.00%
Earnings growth (next 5 years)+50.00%
Revenue growth (last year)+18.34%
P/E ratio46.0
Price/Sales4.76
Price/Book9.19

Competitors

 Today’s
change
Today’s
% change
EBSEmergent BioSolution...+5.15+18.92%
ALDRAlder Biopharmaceuti...+0.90+4.20%
RGENRepligen Corp-0.18-0.57%
DERMDermira Inc+0.84+2.81%
Data as of 4:02pm ET, 12/09/2016

Financials

Next reporting dateMarch 8, 2017
EPS forecast (this quarter)$0.22
Annual revenue (last year)$144.4M
Annual profit (last year)$14.0M
Net profit margin9.70%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
President, CEO, Director &
Secretary
Jack A. Khattar
CFO, Vice President &
Head-Investor Relations
Gregory S. Patrick
Corporate headquarters
Rockville, Maryland

Forecasts